Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Turnover Ratios
Average No. Days
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
The operational activity ratios indicate a profound transformation in efficiency and asset management from 2020 through 2023. The company transitioned from a state of extreme operational latency to a highly streamlined model characterized by rapid asset turnover and a significantly compressed cash cycle.
- Inventory Management Efficiency
- A massive acceleration in inventory movement is evident, with the inventory turnover ratio rising consistently from 0.17 in 2020 to 23.23 in 2023. This is mirrored by the average inventory processing period, which collapsed from an unsustainable 2,141 days in 2020 to only 16 days by the end of 2023, suggesting a highly optimized supply chain and production output.
- Receivables and Payables Dynamics
- Receivables turnover saw a sharp increase from 0.14 in 2020 to a peak of 13.31 in 2022, before moderating to 7.48 in 2023. Consequently, the average receivable collection period dropped from 2,539 days in 2020 to 27 days in 2022, though it lengthened slightly to 49 days in 2023. Payables turnover remained relatively stable after an initial jump in 2021, with the payment period settling between 33 and 42 days from 2021 to 2023.
- Operating and Cash Conversion Cycles
- The operating cycle experienced a drastic reduction, falling from 4,680 days in 2020 to 65 days in 2023. This efficiency gain is further reflected in the cash conversion cycle, which declined from 3,835 days in 2020 to 25 days in 2023. This trend demonstrates a significant improvement in the speed at which cash is recovered from investments in operating assets.
- Working Capital Utilization
- Working capital turnover peaked at 2.55 in 2020 and exhibited a downward trend thereafter, reaching 0.91 in 2023. This decline suggests that the growth in working capital has outpaced the growth in sales, or that the company is maintaining a larger liquidity buffer relative to its current revenue generation.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Inventory Turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of sales | 4,693) | 5,416) | 2,617) | 8) | —) | |
| Inventory | 202) | 949) | 1,441) | 47) | —) | |
| Short-term Activity Ratio | ||||||
| Inventory turnover1 | 23.23 | 5.71 | 1.82 | 0.17 | — | |
| Benchmarks | ||||||
| Inventory Turnover, Competitors2 | ||||||
| AbbVie Inc. | 4.98 | 4.87 | 5.58 | — | — | |
| Amgen Inc. | 0.89 | 1.30 | 1.58 | — | — | |
| Bristol-Myers Squibb Co. | 4.02 | 4.33 | 4.74 | — | — | |
| Danaher Corp. | 3.80 | 4.03 | 4.16 | — | — | |
| Eli Lilly & Co. | 1.23 | 1.54 | 1.88 | — | — | |
| Gilead Sciences Inc. | 3.64 | 3.75 | 4.08 | — | — | |
| Johnson & Johnson | 2.37 | 2.49 | 2.87 | — | — | |
| Merck & Co. Inc. | 2.54 | 2.95 | 2.29 | — | — | |
| Pfizer Inc. | 2.45 | 3.82 | 3.40 | — | — | |
| Regeneron Pharmaceuticals Inc. | 0.70 | 0.65 | 1.25 | — | — | |
| Thermo Fisher Scientific Inc. | 5.06 | 4.60 | 3.88 | — | — | |
| Vertex Pharmaceuticals Inc. | 1.71 | 2.35 | 2.56 | — | — | |
| Inventory Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 2.55 | 3.06 | 3.11 | — | — | |
| Inventory Turnover, Industry | ||||||
| Health Care | 7.36 | 7.85 | 7.90 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Inventory turnover = Cost of sales ÷ Inventory
= 4,693 ÷ 202 = 23.23
2 Click competitor name to see calculations.
The operational data reveals a significant acceleration in inventory efficiency between 2020 and 2023. A consistent and sharp upward trajectory in the inventory turnover ratio indicates a transition toward a lean inventory management model, characterized by a rapid increase in the velocity of stock movement relative to the cost of sales.
- Cost of Sales Trends
- A massive expansion in the cost of sales is observed from 2020 to 2022, rising from 8 million USD to a peak of 5,416 million USD. In 2023, this figure experienced a slight contraction to 4,693 million USD, though it remained several orders of magnitude higher than the 2020 baseline.
- Inventory Volume Dynamics
- Inventory levels peaked in 2021 at 1,441 million USD. Following this peak, a substantial downward trend occurred, with inventory decreasing to 949 million USD in 2022 and further plummeting to 202 million USD by December 31, 2023. This represents a sharp reduction in capital tied up in physical stock.
- Inventory Turnover Interpretation
- The inventory turnover ratio rose exponentially from 0.17 in 2020 to 23.23 in 2023. This increase is the result of the divergence between high cost of sales and aggressively reduced inventory levels. The data indicates that the organization shifted from a phase of heavy accumulation to a phase of high utilization, drastically reducing the average time inventory is held before being sold.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Receivables Turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net product sales | 6,671) | 18,435) | 17,675) | 200) | —) | |
| Accounts receivable, net | 892) | 1,385) | 3,175) | 1,391) | 5) | |
| Short-term Activity Ratio | ||||||
| Receivables turnover1 | 7.48 | 13.31 | 5.57 | 0.14 | 0.00 | |
| Benchmarks | ||||||
| Receivables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 4.87 | 5.16 | 5.63 | — | — | |
| Amgen Inc. | 3.70 | 4.46 | 4.96 | — | — | |
| Bristol-Myers Squibb Co. | 4.93 | 5.48 | 5.65 | — | — | |
| Danaher Corp. | 6.09 | 6.40 | 6.36 | — | — | |
| Eli Lilly & Co. | 3.75 | 4.14 | 4.24 | — | — | |
| Gilead Sciences Inc. | 5.78 | 5.65 | 6.01 | — | — | |
| Johnson & Johnson | 5.73 | 5.88 | 6.14 | — | — | |
| Merck & Co. Inc. | 5.81 | 6.27 | 5.28 | — | — | |
| Pfizer Inc. | 5.33 | 9.24 | 7.16 | — | — | |
| Regeneron Pharmaceuticals Inc. | 2.31 | 2.28 | 2.66 | — | — | |
| Thermo Fisher Scientific Inc. | 5.21 | 5.53 | 4.92 | — | — | |
| Vertex Pharmaceuticals Inc. | 6.31 | 6.19 | 6.66 | — | — | |
| Receivables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 4.96 | 5.76 | 5.54 | — | — | |
| Receivables Turnover, Industry | ||||||
| Health Care | 7.66 | 8.22 | 8.00 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Receivables turnover = Net product sales ÷ Accounts receivable, net
= 6,671 ÷ 892 = 7.48
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals significant volatility in the efficiency of receivables management between 2020 and 2023. The company experienced an initial phase of low collection efficiency followed by a period of rapid optimization, ending with a moderate decline as sales volumes contracted.
- Net Product Sales Trends
- A massive expansion in revenue occurred between 2020 and 2022, with sales increasing from 200 million to a peak of 18.4 billion. This growth trajectory reversed in 2023, with net product sales declining to 6.7 billion.
- Accounts Receivable Dynamics
- Net accounts receivable grew sharply in 2020 and 2021, peaking at 3.2 billion. Subsequently, a consistent downward trend was observed, with receivables decreasing to 1.4 billion in 2022 and further to 892 million by the end of 2023.
- Receivables Turnover Efficiency
- The receivables turnover ratio demonstrates a dramatic shift in operational efficiency. An initial ratio of 0.14 in 2020 indicates an extremely slow conversion of receivables into cash. This improved substantially to 5.57 in 2021 and reached a peak of 13.31 in 2022, suggesting highly optimized collection processes during the peak sales period. In 2023, the ratio declined to 7.48, reflecting a slowdown in turnover that corresponds with the overall reduction in sales volume.
The correlation between peaking sales and the peaking turnover ratio in 2022 suggests that the company successfully scaled its credit and collection infrastructure to match its commercial growth. However, the subsequent decline in 2023 indicates that while receivables are lower in absolute terms, they are not being cleared as rapidly relative to the current lower volume of sales.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Payables Turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of sales | 4,693) | 5,416) | 2,617) | 8) | —) | |
| Accounts payable | 520) | 487) | 302) | 18) | 7) | |
| Short-term Activity Ratio | ||||||
| Payables turnover1 | 9.03 | 11.12 | 8.67 | 0.43 | 0.00 | |
| Benchmarks | ||||||
| Payables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 5.54 | 5.94 | 6.05 | — | — | |
| Amgen Inc. | 5.32 | 4.08 | 4.72 | — | — | |
| Bristol-Myers Squibb Co. | 3.28 | 3.33 | 3.37 | — | — | |
| Danaher Corp. | 5.58 | 5.45 | 4.48 | — | — | |
| Eli Lilly & Co. | 2.73 | 3.43 | 4.38 | — | — | |
| Gilead Sciences Inc. | 11.81 | 6.25 | 9.36 | — | — | |
| Johnson & Johnson | 2.76 | 2.66 | 2.70 | — | — | |
| Merck & Co. Inc. | 4.11 | 4.08 | 2.96 | — | — | |
| Pfizer Inc. | 3.72 | 5.04 | 5.53 | — | — | |
| Regeneron Pharmaceuticals Inc. | 2.99 | 2.65 | 4.32 | — | — | |
| Thermo Fisher Scientific Inc. | 8.97 | 7.67 | 6.83 | — | — | |
| Vertex Pharmaceuticals Inc. | 3.46 | 3.55 | 4.64 | — | — | |
| Payables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 4.25 | 4.28 | 4.23 | — | — | |
| Payables Turnover, Industry | ||||||
| Health Care | 5.97 | 5.79 | 5.84 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Payables turnover = Cost of sales ÷ Accounts payable
= 4,693 ÷ 520 = 9.03
2 Click competitor name to see calculations.
Operational activity reflects a period of exponential growth between 2020 and 2022, followed by a phase of stabilization in 2023. The cost of sales increased drastically from 8 million USD in 2020 to a peak of 5,416 million USD in 2022, before moderating to 4,693 million USD in 2023. During the same period, accounts payable exhibited a consistent upward trajectory, rising from 7 million USD in 2019 to 520 million USD by the end of 2023.
- Payables Turnover Trends
- A significant acceleration in the payables turnover ratio occurred between 2020 and 2022, moving from 0.43 to a peak of 11.12. This rapid increase indicates a substantial rise in the frequency of supplier payments as the scale of operations expanded. In 2023, the ratio declined to 9.03, reflecting a reduction in the velocity of payable settlements.
- Analysis of Operational Efficiency and Obligations
- The 2023 fiscal year shows a divergence between procurement costs and outstanding obligations. While the cost of sales decreased from 5,416 million USD to 4,693 million USD, accounts payable continued to grow, reaching 520 million USD. This combination resulted in the observed decline in the turnover ratio, suggesting a shift toward longer payment terms or an increase in the average balance owed to suppliers relative to the volume of goods and services consumed.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Working Capital Turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current assets | 10,325) | 13,431) | 16,071) | 6,298) | 1,129) | |
| Less: Current liabilities | 3,015) | 4,923) | 9,128) | 4,389) | 143) | |
| Working capital | 7,310) | 8,508) | 6,943) | 1,909) | 986) | |
| Net product sales | 6,671) | 18,435) | 17,675) | 200) | —) | |
| Short-term Activity Ratio | ||||||
| Working capital turnover1 | 0.91 | 2.17 | 2.55 | 0.10 | 0.00 | |
| Benchmarks | ||||||
| Working Capital Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | 2.25 | 3.82 | 3.37 | — | — | |
| Bristol-Myers Squibb Co. | 4.60 | 8.30 | 3.95 | — | — | |
| Danaher Corp. | 4.22 | 4.20 | 8.40 | — | — | |
| Eli Lilly & Co. | — | 31.84 | 8.33 | — | — | |
| Gilead Sciences Inc. | 5.61 | 8.42 | 8.54 | — | — | |
| Johnson & Johnson | 11.81 | — | 5.95 | — | — | |
| Merck & Co. Inc. | 9.29 | 5.16 | 7.62 | — | — | |
| Pfizer Inc. | — | 11.09 | 4.83 | — | — | |
| Regeneron Pharmaceuticals Inc. | 0.82 | 0.96 | 1.59 | — | — | |
| Thermo Fisher Scientific Inc. | 4.05 | 5.46 | 5.87 | — | — | |
| Vertex Pharmaceuticals Inc. | 0.93 | 0.85 | 1.02 | — | — | |
| Working Capital Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 6.68 | 7.25 | 5.87 | — | — | |
| Working Capital Turnover, Industry | ||||||
| Health Care | 10.99 | 11.30 | 8.57 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Working capital turnover = Net product sales ÷ Working capital
= 6,671 ÷ 7,310 = 0.91
2 Click competitor name to see calculations.
The analysis of operating activity between 2019 and 2023 reveals a period of extreme volatility in resource utilization and revenue generation. Working capital experienced a consistent upward trajectory from 2019, increasing from US$ 986 million to a peak of US$ 8,508 million in 2022, before contracting to US$ 7,310 million in 2023. This expansion of liquid assets occurred alongside a dramatic fluctuation in net product sales, which peaked in 2022 before experiencing a significant decline.
- Net Product Sales Trends
- A massive acceleration in commercial activity is observed between 2020 and 2021, with sales rising from US$ 200 million to US$ 17,675 million. This growth peaked in 2022 at US$ 18,435 million, followed by a sharp contraction in 2023, where sales fell to US$ 6,671 million, representing a decrease of approximately 63.8% from the previous year.
- Working Capital Turnover Performance
- The working capital turnover ratio mirrors the volatility of product sales. An initial ratio of 0.10 in 2020 surged to 2.55 in 2021, indicating a highly efficient conversion of working capital into sales during the initial commercial scaling phase. However, a downward trend followed, with the ratio declining to 2.17 in 2022 and dropping further to 0.91 in 2023.
- Efficiency and Resource Utilization
- The decline in the turnover ratio to 0.91 by the end of 2023 suggests a diminishing capacity to generate sales relative to the capital invested in current assets and liabilities. While working capital was reduced by approximately 14% in 2023, the far more aggressive decline in net product sales resulted in a significant reduction in operational efficiency, bringing the turnover ratio below the 1.0 threshold.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Average Inventory Processing Period
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Inventory turnover | 23.23 | 5.71 | 1.82 | 0.17 | — | |
| Short-term Activity Ratio (no. days) | ||||||
| Average inventory processing period1 | 16 | 64 | 201 | 2,141 | — | |
| Benchmarks (no. days) | ||||||
| Average Inventory Processing Period, Competitors2 | ||||||
| AbbVie Inc. | 73 | 75 | 65 | — | — | |
| Amgen Inc. | 411 | 281 | 231 | — | — | |
| Bristol-Myers Squibb Co. | 91 | 84 | 77 | — | — | |
| Danaher Corp. | 96 | 91 | 88 | — | — | |
| Eli Lilly & Co. | 298 | 237 | 194 | — | — | |
| Gilead Sciences Inc. | 100 | 97 | 89 | — | — | |
| Johnson & Johnson | 154 | 147 | 127 | — | — | |
| Merck & Co. Inc. | 144 | 124 | 159 | — | — | |
| Pfizer Inc. | 149 | 95 | 107 | — | — | |
| Regeneron Pharmaceuticals Inc. | 519 | 562 | 292 | — | — | |
| Thermo Fisher Scientific Inc. | 72 | 79 | 94 | — | — | |
| Vertex Pharmaceuticals Inc. | 214 | 156 | 143 | — | — | |
| Average Inventory Processing Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 143 | 119 | 117 | — | — | |
| Average Inventory Processing Period, Industry | ||||||
| Health Care | 50 | 46 | 46 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 23.23 = 16
2 Click competitor name to see calculations.
The financial metrics reveal a substantial improvement in inventory management efficiency between 2020 and 2023, characterized by a rapid acceleration in inventory turnover and a corresponding drastic reduction in the average processing period.
- Inventory Turnover
- A consistent and sharp upward trend is observed in the inventory turnover ratio. Starting from a low of 0.17 in 2020, the ratio increased to 1.82 in 2021, 5.71 in 2022, and reached 23.23 by the end of 2023. This trajectory indicates a significant increase in the frequency with which inventory is sold and replaced over the reporting period.
- Average Inventory Processing Period
- The average inventory processing period exhibited a mirrored downward trend, decreasing from an exceptionally high 2,141 days in 2020 to 201 days in 2021, 64 days in 2022, and finally 16 days in 2023. This decline represents a transition from prolonged inventory holding times to a highly streamlined distribution cycle.
The inverse correlation between these two metrics confirms a transition toward operational maturity. The reduction of the processing period to 16 days by 2023 suggests that the supply chain and demand fulfillment processes have been optimized, resulting in significantly higher liquidity of current assets and reduced capital tied up in unsold stock.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Average Receivable Collection Period
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Receivables turnover | 7.48 | 13.31 | 5.57 | 0.14 | 0.00 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average receivable collection period1 | 49 | 27 | 66 | 2,539 | — | |
| Benchmarks (no. days) | ||||||
| Average Receivable Collection Period, Competitors2 | ||||||
| AbbVie Inc. | 75 | 71 | 65 | — | — | |
| Amgen Inc. | 99 | 82 | 74 | — | — | |
| Bristol-Myers Squibb Co. | 74 | 67 | 65 | — | — | |
| Danaher Corp. | 60 | 57 | 57 | — | — | |
| Eli Lilly & Co. | 97 | 88 | 86 | — | — | |
| Gilead Sciences Inc. | 63 | 65 | 61 | — | — | |
| Johnson & Johnson | 64 | 62 | 59 | — | — | |
| Merck & Co. Inc. | 63 | 58 | 69 | — | — | |
| Pfizer Inc. | 69 | 40 | 51 | — | — | |
| Regeneron Pharmaceuticals Inc. | 158 | 160 | 137 | — | — | |
| Thermo Fisher Scientific Inc. | 70 | 66 | 74 | — | — | |
| Vertex Pharmaceuticals Inc. | 58 | 59 | 55 | — | — | |
| Average Receivable Collection Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 74 | 63 | 66 | — | — | |
| Average Receivable Collection Period, Industry | ||||||
| Health Care | 48 | 44 | 46 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 7.48 = 49
2 Click competitor name to see calculations.
An analysis of short-term operating activity reveals a period of extreme volatility followed by a transition toward stabilization in credit collection efficiency between 2020 and 2023.
- Receivables Turnover
- A significant upward trajectory is observed from 2020 to 2022, with the turnover ratio increasing from 0.14 to a peak of 13.31. This rapid acceleration indicates a substantial improvement in the efficiency of converting receivables into cash. However, this trend reversed in 2023, as the ratio declined to 7.48, suggesting a reduction in the velocity of credit recovery during the most recent fiscal year.
- Average Receivable Collection Period
- The collection period experienced a drastic contraction, falling from 2,539 days in 2020 to 66 days in 2021. This efficiency peaked in 2022, when the period reached a minimum of 27 days. In 2023, the collection period extended to 49 days, marking a moderate increase in the time required to collect outstanding payments, though the figure remains significantly lower than the levels recorded in 2020 and 2021.
The correlation between the turnover ratio and the collection period confirms a shift from an initial phase of negligible collection activity to a highly efficient operational state, followed by a recent moderate expansion of the credit cycle.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Operating Cycle
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | 16 | 64 | 201 | 2,141 | — | |
| Average receivable collection period | 49 | 27 | 66 | 2,539 | — | |
| Short-term Activity Ratio | ||||||
| Operating cycle1 | 65 | 91 | 267 | 4,680 | — | |
| Benchmarks | ||||||
| Operating Cycle, Competitors2 | ||||||
| AbbVie Inc. | 148 | 146 | 130 | — | — | |
| Amgen Inc. | 510 | 363 | 305 | — | — | |
| Bristol-Myers Squibb Co. | 165 | 151 | 142 | — | — | |
| Danaher Corp. | 156 | 148 | 145 | — | — | |
| Eli Lilly & Co. | 395 | 325 | 280 | — | — | |
| Gilead Sciences Inc. | 163 | 162 | 150 | — | — | |
| Johnson & Johnson | 218 | 209 | 186 | — | — | |
| Merck & Co. Inc. | 207 | 182 | 228 | — | — | |
| Pfizer Inc. | 218 | 135 | 158 | — | — | |
| Regeneron Pharmaceuticals Inc. | 677 | 722 | 429 | — | — | |
| Thermo Fisher Scientific Inc. | 142 | 145 | 168 | — | — | |
| Vertex Pharmaceuticals Inc. | 272 | 215 | 198 | — | — | |
| Operating Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 217 | 182 | 183 | — | — | |
| Operating Cycle, Industry | ||||||
| Health Care | 98 | 90 | 92 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 16 + 49 = 65
2 Click competitor name to see calculations.
The operating cycle experienced a drastic contraction between 2020 and 2023, indicating a significant acceleration in the ability to convert current assets into cash. This trend is characterized by a shift from anomalous, high-duration periods in 2020 to a streamlined operational model by the end of 2023, resulting in a substantial improvement in overall liquidity and working capital efficiency.
- Average Inventory Processing Period
- A sharp downward trend is observed, with the period decreasing from 2,141 days in 2020 to 16 days in 2023. This precipitous decline suggests a fundamental shift in inventory management and supply chain velocity, moving from extreme stagnation to a highly efficient turnover rate.
- Average Receivable Collection Period
- The collection period declined dramatically from 2,539 days in 2020 to a low of 27 days in 2022. While a modest increase to 49 days occurred in 2023, the metric remains significantly lower than the 2020 baseline, reflecting a more effective process for converting credit sales into cash.
- Operating Cycle
- The total operating cycle was reduced from 4,680 days in 2020 to 65 days in 2023. This compression is the direct result of the combined reductions in both inventory processing and receivable collection times, signifying a vastly optimized cash-to-cash cycle.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Average Payables Payment Period
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Payables turnover | 9.03 | 11.12 | 8.67 | 0.43 | 0.00 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average payables payment period1 | 40 | 33 | 42 | 845 | — | |
| Benchmarks (no. days) | ||||||
| Average Payables Payment Period, Competitors2 | ||||||
| AbbVie Inc. | 66 | 61 | 60 | — | — | |
| Amgen Inc. | 69 | 90 | 77 | — | — | |
| Bristol-Myers Squibb Co. | 111 | 109 | 108 | — | — | |
| Danaher Corp. | 65 | 67 | 82 | — | — | |
| Eli Lilly & Co. | 134 | 106 | 83 | — | — | |
| Gilead Sciences Inc. | 31 | 58 | 39 | — | — | |
| Johnson & Johnson | 132 | 137 | 135 | — | — | |
| Merck & Co. Inc. | 89 | 89 | 123 | — | — | |
| Pfizer Inc. | 98 | 72 | 66 | — | — | |
| Regeneron Pharmaceuticals Inc. | 122 | 138 | 84 | — | — | |
| Thermo Fisher Scientific Inc. | 41 | 48 | 53 | — | — | |
| Vertex Pharmaceuticals Inc. | 106 | 103 | 79 | — | — | |
| Average Payables Payment Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 86 | 85 | 86 | — | — | |
| Average Payables Payment Period, Industry | ||||||
| Health Care | 61 | 63 | 63 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 9.03 = 40
2 Click competitor name to see calculations.
The analysis reveals a significant transition in the management of accounts payable between 2020 and 2023. An initial period of extreme volatility was followed by a normalization of payment cycles and a stabilization of operational efficiency.
- Payables Turnover
- A substantial increase in the turnover ratio is observed from 0.43 in 2020 to 8.67 in 2021, eventually peaking at 11.12 in 2022. This trajectory indicates a rapid acceleration in the frequency with which obligations to suppliers were settled. A slight moderation occurred in 2023, with the ratio declining to 9.03, suggesting a stabilization of procurement and payment activities.
- Average Payables Payment Period
- The payment period exhibited a drastic reduction from an exceptional 845 days in 2020 to 42 days in 2021. This shift represents a move from an anomalous payment cycle to a standard operational timeframe. The period reached a minimum of 33 days in 2022 before slightly increasing to 40 days in 2023. This trend demonstrates a consistent and disciplined approach to managing short-term liabilities over the last three reporting periods.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Cash Conversion Cycle
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | 16 | 64 | 201 | 2,141 | — | |
| Average receivable collection period | 49 | 27 | 66 | 2,539 | — | |
| Average payables payment period | 40 | 33 | 42 | 845 | — | |
| Short-term Activity Ratio | ||||||
| Cash conversion cycle1 | 25 | 58 | 225 | 3,835 | — | |
| Benchmarks | ||||||
| Cash Conversion Cycle, Competitors2 | ||||||
| AbbVie Inc. | 82 | 85 | 70 | — | — | |
| Amgen Inc. | 441 | 273 | 228 | — | — | |
| Bristol-Myers Squibb Co. | 54 | 42 | 34 | — | — | |
| Danaher Corp. | 91 | 81 | 63 | — | — | |
| Eli Lilly & Co. | 261 | 219 | 197 | — | — | |
| Gilead Sciences Inc. | 132 | 104 | 111 | — | — | |
| Johnson & Johnson | 86 | 72 | 51 | — | — | |
| Merck & Co. Inc. | 118 | 93 | 105 | — | — | |
| Pfizer Inc. | 120 | 63 | 92 | — | — | |
| Regeneron Pharmaceuticals Inc. | 555 | 584 | 345 | — | — | |
| Thermo Fisher Scientific Inc. | 101 | 97 | 115 | — | — | |
| Vertex Pharmaceuticals Inc. | 166 | 112 | 119 | — | — | |
| Cash Conversion Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 131 | 97 | 97 | — | — | |
| Cash Conversion Cycle, Industry | ||||||
| Health Care | 37 | 27 | 29 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 16 + 49 – 40 = 25
2 Click competitor name to see calculations.
A substantial contraction in the cash conversion cycle is observed between 2020 and 2023, indicating a significant acceleration in the efficiency of operating working capital. The cycle transitioned from an extreme outlier of 3,835 days in 2020 to a lean 25 days by the end of 2023, reflecting a fundamental shift in the company's operational velocity.
- Average Inventory Processing Period
- An aggressive downward trend is evident in inventory management. The processing period decreased from 2,141 days in 2020 to 16 days in 2023. This precipitous decline suggests a transition from early-stage stockpiling or low-volume production to a highly optimized, high-turnover distribution model.
- Average Receivable Collection Period
- The time required to collect payments from customers saw a massive reduction from 2,539 days in 2020 to 49 days in 2023. While a slight increase occurred between 2022 (27 days) and 2023 (49 days), the overall trajectory demonstrates a marked improvement in credit management and cash inflow efficiency compared to the initial period.
- Average Payables Payment Period
- The payment period for suppliers decreased from 845 days in 2020 to 40 days in 2023. The stabilization of this metric between 33 and 42 days from 2021 through 2023 indicates the establishment of a normalized procurement and payment cadence.
- Cash Conversion Cycle Synthesis
- The overarching trend reveals a move toward extreme liquidity efficiency. The drastic reductions in both inventory and receivable periods outweighed the reduction in the payables period, resulting in a net reduction of the cash conversion cycle. By 2023, the operating cycle had become highly streamlined, minimizing the time capital is tied up in the production and sales process.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?